{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T06:03:02Z","timestamp":1789365782451,"version":"build-2803163510"},"reference-count":92,"publisher":"Open Exploration Publishing","license":[{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Explor Target Antitumor Ther"],"accepted":{"date-parts":[[2026,8,12]]},"abstract":"<jats:p xml:lang=\"en\">With national breast cancer screening programs leading to earlier diagnosis and improved treatments, more women are achieving long-term remission. However, this has resulted in rising rates of cardiotoxicity in breast cancer survivors consequent to their cancer therapies. Anthracyclines, a cornerstone treatment in breast cancer, carry a significant risk of short- and long-term cardiotoxicity through inhibition of topoisomerase II, preventing DNA repair and increasing oxidative stress. This most commonly manifests in the form of left ventricular (LV) systolic dysfunction or heart failure, and in severe cases, death. Many of the other treatments, including taxanes, cyclophosphamide, human epidermal growth factor receptor 2 inhibitors, immunotherapies, hormone therapies, and radiotherapy, also carry a risk of cardiac injury in the form of heart failure, arrhythmias, myocarditis, and pericardial disease. Surveillance has traditionally been performed by monitoring LV ejection fraction by transthoracic echocardiography. However, this has been found to be a late marker of cardiotoxicity, with damage potentially irreversible, and may reflect a missed opportunity for early intervention. Research has focused on identifying cardiac biomarkers and advanced imaging techniques, including strain analysis, to detect subclinical myocardial injury or dysfunction prior to irreversible damage, with LV global longitudinal strain a sensitive marker of subclinical LV systolic dysfunction and superior predictor of future cardiovascular events. Further research is needed to establish standardized guidelines on surveillance and management of this vulnerable patient cohort.<\/jats:p>","DOI":"10.37349\/etat.2026.1002401","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T05:15:39Z","timestamp":1789362939000},"update-policy":"https:\/\/doi.org\/10.37349\/open_exploration_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cardiotoxicity in breast cancer patients treated with chemoradiotherapy"],"prefix":"10.37349","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8752-0687","authenticated-orcid":false,"given":"Peter","family":"Emerson","sequence":"first","affiliation":[{"name":"Department of Cardiology, Westmead Hospital, Westmead 2145, Australia; Westmead Clinical School, The University of Sydney, Camperdown 2050, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6045-7780","authenticated-orcid":false,"given":"Liza","family":"Thomas","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Westmead Hospital, Westmead 2145, Australia; Westmead Clinical School, The University of Sydney, Camperdown 2050, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"21850","published-online":{"date-parts":[[2026,9,14]]},"reference":[{"key":"ref1","unstructured":"Menon G, Alkabban FM, Ferguson T. Breast Cancer. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2025.1622954","article-title":"Global burden and projections of breast cancer incidence and mortality to 2050: a comprehensive analysis of GLOBOCAN data","volume":"13","author":"Freihat","year":"2025","journal-title":"Front Public Health"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Arzanova E, Mayrovitz HN. The Epidemiology of Breast Cancer","DOI":"10.36255\/exon-publications-breast-cancer-epidemiology"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"471","DOI":"10.3322\/caac.21867","article-title":"Breast cancer: The good, the bad, and an important call to effective risk reduction strategies","volume":"74","author":"Kaklamani","year":"2024","journal-title":"CA: Cancer J Clin"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2024.103862","article-title":"Survival feature and trend of female breast cancer: A comprehensive review of survival analysis from cancer registration data","volume":"79","author":"Tang","year":"2025","journal-title":"Breast"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2023.41.16_suppl.12078","article-title":"Cardiac dysfunction (CD) among breast cancer survivors (BCS): Role of cardiotoxic therapy and cardiovascular risk factors","volume":"41","author":"Bostany","year":"2023","journal-title":"J Clin Oncol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s10549-011-1843-1","article-title":"Comparison of breast cancer recurrence risk and cardiovascular disease incidence risk among postmenopausal women with breast cancer","volume":"131","author":"Bardia","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"ref8","unstructured":"Czajka ML, Pfeifer C. Breast Cancer Surgery. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026."},{"key":"ref9","article-title":"Systemic Therapy for Early-Stage Breast Cancer: What the Plastic Surgeon Should Know","volume":"17","author":"Teven","year":"2017","journal-title":"Eplasty"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1634\/theoncologist.2017-0672","article-title":"Adjuvant Anthracyclines in Breast Cancer: What Is Their Role?","volume":"23","author":"Shah","year":"2018","journal-title":"Oncologist"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.breast.2022.06.007","article-title":"Anthracyclines in the treatment of early breast cancer friend or foe?","volume":"65","author":"Vuger","year":"2022","journal-title":"Breast"},{"key":"ref12","unstructured":"Douedi S, Carson MP. Anthracycline Medications (Doxorubicin). In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026."},{"key":"ref13","unstructured":"Venkatesh P, Kasi A. Anthracyclines. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023."},{"key":"ref14","unstructured":"Ismail U, Killeen RB. Taxane Toxicity. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026."},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12113323","article-title":"Mechanisms of Taxane Resistance","volume":"12","author":"Maloney","year":"2020","journal-title":"Cancers"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"4486","DOI":"10.3390\/curroncol31080335","article-title":"The Omission of Anthracycline Chemotherapy in Women with Early HER2-Negative Breast Cancer\u2014A Systematic Review and Meta-Analysis","volume":"31","author":"Giffoni","year":"2024","journal-title":"Curr Oncol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.01300","article-title":"Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium","volume":"9","author":"Falzone","year":"2018","journal-title":"Front Pharmacol"},{"key":"ref18","unstructured":"Ogino MH, Tadi P. Cyclophosphamide. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026."},{"key":"ref19","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.clbc.2013.10.018","article-title":"Feasibility of 4 Cycles of Docetaxel and Cyclophosphamide Every 14 Days as an Adjuvant Regimen for Breast Cancer: A Wisconsin Oncology Network Study","volume":"14","author":"Burkard","year":"2014","journal-title":"Clin Breast Cancer"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3390\/ph16101450","article-title":"The History and Development of HER2 Inhibitors","volume":"16","author":"Xia","year":"2023","journal-title":"Pharmaceuticals"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12082081","article-title":"The Changing Paradigm for the Treatment of HER2-Positive Breast Cancer","volume":"12","author":"Patel","year":"2020","journal-title":"Cancers"},{"key":"ref22","first-page":"171","article-title":"Breast Cancer Treatment","volume":"104","author":"Trayes","year":"2021","journal-title":"Am Fam Physician"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"339","DOI":"10.2147\/bctt.s506949","article-title":"Current Status of Breast Cancer Immunotherapy and Prognosis-Related Markers","volume":"17","author":"Xu","year":"2025","journal-title":"Breast Cancer: Targets Ther"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25147517","article-title":"Immunotherapy in Breast Cancer","volume":"25","author":"Dvir","year":"2024","journal-title":"Int J Mol Sci"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1159\/000160910","article-title":"Endocrine Therapy\u2014What Else?","volume":"3","author":"Marth","year":"2008","journal-title":"Breast Care"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"231","DOI":"10.4331\/wjbc.v6.i3.231","article-title":"Current medical treatment of estrogen receptor-positive breast cancer","volume":"6","author":"Lumachi","year":"2015","journal-title":"World J Biol Chem"},{"key":"ref27","unstructured":"Patel P, Jacobs TF. Tamoxifen. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026."},{"key":"ref28","unstructured":"Fong MK, Patel P. Aromatase Inhibitors. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026."},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Jaffray DA, Gospodarowicz MK. Radiation Therapy for Cancer","DOI":"10.1596\/978-1-4648-0349-9_ch14"},{"key":"ref30","unstructured":"Kim CS, Algan O. Radiation Therapy for Early-Stage Breast Cancer. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026."},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20120601","article-title":"Breast cancer subtypes: response to radiotherapy and potential radiosensitisation","volume":"86","author":"Langlands","year":"2014","journal-title":"Br J Radiol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.hlc.2023.06.864","article-title":"Alterations in Left Atrial Strain in Breast Cancer Patients Immediately Post Anthracycline Exposure","volume":"33","author":"Emerson","year":"2024","journal-title":"Heart Lung Circ"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.3390\/medicina61040709","article-title":"Overview of Oncology: Drug-Induced Cardiac Toxicity","volume":"61","author":"Kundnani","year":"2025","journal-title":"Medicina"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1002\/ejhf.70005","article-title":"Heart Failure with Preserved Ejection Fraction in Cancer Patients and Survivors. A Scientific Statement of the Heart Failure Association of the ESC and the ESC Council of Cardio-Oncology","volume":"27","author":"Keramida","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"5149","DOI":"10.2147\/cmar.s313874","article-title":"Cardiotoxicity and Cardiac Monitoring Among Anthracycline-Treated Cancer Patients: A Retrospective Cohort Study","volume":"13","author":"Alkofide","year":"2021","journal-title":"Cancer Manag Res"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1406247","article-title":"An update of the molecular mechanisms underlying anthracycline induced cardiotoxicity","volume":"15","author":"Xie","year":"2024","journal-title":"Front Pharmacol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22157764","article-title":"Cardiomyocyte Proliferation as a Source of New Myocyte Development in the Adult Heart","volume":"22","author":"Johnson","year":"2021","journal-title":"Int J Mol Sci"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.16920","article-title":"Delayed Onset Anthracycline-Associated Cardiotoxicity Presenting as Acute Decompensated Heart Failure Seven Years After Chemotherapy Completion","volume":"13","author":"Tran","year":"2021","journal-title":"Cureus"},{"key":"ref39","unstructured":"Johnson M, Keyes D. Anthracycline Toxicity. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026."},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1007\/s10741-025-10531-0","article-title":"Cancer therapy-induced cardiotoxicity: mechanisms and mitigations","volume":"30","author":"Shil","year":"2025","journal-title":"Heart Fail Rev"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2025.103168","article-title":"HER2-targeted therapies and cardiotoxicity: From major concern to manageable risk","volume":"50","author":"Pamungkas","year":"2025","journal-title":"Curr Probl Cardiol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1002\/ejhf.2289","article-title":"Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta-analysis","volume":"23","author":"Rubio-Infante","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1186\/s40360-019-0339-1","article-title":"Aromatase inhibitors and risk of cardiovascular events in breast cancer patients: a systematic review and meta-analysis","volume":"20","author":"He","year":"2019","journal-title":"BMC Pharmacol Toxicol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.rpor.2019.12.008","article-title":"Cardiotoxicity of breast cancer radiotherapy\u2014overview of current results","volume":"25","author":"Soumarov\u00e1","year":"2020","journal-title":"Rep Pract Oncol Radiother"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.847012","article-title":"Cardiotoxicity of Anticancer Drugs: Molecular Mechanisms and Strategies for Cardioprotection","volume":"9","author":"Morelli","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/S0140-6736(23)00285-4","article-title":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG); Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG). Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials","volume":"401","year":"2023","journal-title":"Lancet"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1177\/2324709613480346","article-title":"Cyclophosphamide-Induced Cardiomyopathy","volume":"1","author":"Dhesi","year":"2013","journal-title":"J Investig Med High Impact Case Rep"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.83012","article-title":"Cardiotoxic Effects of HER2-Targeted Therapies: Insights From a Retrospective Study at a Romanian Oncology Center","volume":"17","author":"Kajanto","year":"2025","journal-title":"Cureus"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1097\/hco.0000000000000637","article-title":"Cardiotoxicity of HER2-targeted therapies","volume":"34","author":"Copeland-Halperin","year":"2019","journal-title":"Curr Opin Cardiol"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1056\/nejmoa052306","article-title":"Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer","volume":"353","author":"Piccart-Gebhart","year":"2005","journal-title":"N Engl J Med"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1080\/14737140.2024.2341729","article-title":"Current usage of pembrolizumab in triple negative breast cancer (TNBC)","volume":"24","author":"O'Rourke","year":"2024","journal-title":"Expert Rev Anticancer Ther"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2026.1762011","article-title":"Immunotherapy-related cardiovascular toxicity: from mechanisms to management","volume":"17","author":"Xiao","year":"2026","journal-title":"Front Pharmacol"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jare.2020.09.006","article-title":"PD-1\/PDL-1 Inhibitors and Cardiotoxicity; Molecular, Etiological and Management Outlines","volume":"29","author":"Safi","year":"2021","journal-title":"J Adv Res"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-06768-w","article-title":"Cardiotoxicity in cancer immunotherapy: a systematic review and global meta-analysis","volume":"23","author":"Zhou","year":"2025","journal-title":"J Transl Med"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11113133","article-title":"Aromatase Inhibitors and Risk of Metabolic and Cardiovascular Adverse Effects in Breast Cancer Patients\u2014A Systematic Review and Meta-Analysis","volume":"11","author":"Boszkiewicz","year":"2022","journal-title":"J Clin Med"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1210\/jc.2013-1328","article-title":"The Use of Aromatase Inhibitors for Ovulation Induction and Superovulation","volume":"98","author":"Pavone","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1124\/pr.107.08002","article-title":"Vascular Actions of Estrogens: Functional Implications","volume":"60","author":"Miller","year":"2008","journal-title":"Pharmacol Rev"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"e819","DOI":"10.1016\/j.clbc.2018.05.010","article-title":"A Systematic Review of Heart Dose in Breast Radiotherapy","volume":"18","author":"Drost","year":"2018","journal-title":"Clin Breast Cancer"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1742769","article-title":"Cardioprotection for radiation-induced heart disease in breast cancer patients","volume":"16","author":"M\u0119drek","year":"2026","journal-title":"Front Pharmacol"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2025.104581","article-title":"Evaluation of cardiotoxicity following breast cancer irradiation in an Asian cohort in real-world settings","volume":"84","author":"Yang","year":"2025","journal-title":"Breast"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.121.021686","article-title":"Radiation\u2010Induced Cardiovascular Disease: Review of an Underrecognized Pathology","volume":"10","author":"Belzile-Dugas","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.3390\/jcdd9110372","article-title":"Cardiac Biomarkers for the Detection and Management of Cancer Therapy-Related Cardiovascular Toxicity","volume":"9","author":"Zhang","year":"2022","journal-title":"J Cardiovasc Dev Dis"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1136\/jcp.2003.015420","article-title":"Cardiac troponins","volume":"57","author":"Sharma","year":"2004","journal-title":"J Clin Pathol"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"H1","DOI":"10.1152\/ajpheart.00093.2022","article-title":"Myocardial injury, troponin release, and cardiomyocyte death in brief ischemia, failure, and ventricular remodeling","volume":"323","author":"Canty","year":"2022","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1016\/j.jacc.2007.09.021","article-title":"Natriuretic Peptides","volume":"50","author":"Daniels","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"ref66","unstructured":"Novack ML, Zubair M. Natriuretic Peptide B Type Test. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026."},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.49696","article-title":"Recent Advances in Serum Biomarkers for Cardiological Risk Stratification and Insight into the Cardiac Management of the Patients With Hematological Malignancies Treated With Targeted Therapy","volume":"15","author":"Andreescu","year":"2023","journal-title":"Cureus"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s12265-020-10042-3","article-title":"The Role of Biomarkers in Cardio-Oncology","volume":"13","author":"Ananthan","year":"2020","journal-title":"J Cardiovasc Transl Res"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"258","DOI":"10.14797\/mdcj-15-4-258","article-title":"The Role of Cardiovascular Imaging and Serum Biomarkers in Identifying Cardiotoxicity Related to Cancer Therapeutics","volume":"15","author":"Agha","year":"2019","journal-title":"Methodist DeBakey Cardiovasc J"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2014.00277","article-title":"Serum Biomarkers for the Detection of Cardiac Toxicity after Chemotherapy and Radiation Therapy in Breast Cancer Patients","volume":"4","author":"Tian","year":"2014","journal-title":"Front Oncol"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.echo.2025.06.001","article-title":"Guidelines for the Standardization of Adult Echocardiography Reporting: Recommendations From the American Society of Echocardiography","volume":"38","author":"Taub","year":"2025","journal-title":"J Am Soc Echocardiogr"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1093\/ehjci\/jex244","article-title":"Standardization of adult transthoracic echocardiography reporting in agreement with recent chamber quantification, diastolic function, and heart valve disease recommendations: an expert consensus document of the European Association of Cardiovascular Imaging","volume":"18","author":"Galderisi","year":"2017","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40119-025-00399-4","article-title":"2025 Expert Consensus Recommendations for the Diagnostic Requirements in Routine Practices of Transthoracic Echocardiography","volume":"41","author":"Chen","year":"2025","journal-title":"Acta Cardiol Sin"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1093\/ehjci\/jeu192","article-title":"Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"15","author":"Plana","year":"2014","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"ref75","unstructured":"Shams P, Goyal A, Makaryus AN. Left Ventricular Ejection Fraction. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026."},{"key":"ref76","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ijcard.2022.02.024","article-title":"Left atrial strain in cardiac surveillance of bone marrow transplant patients with prior anthracycline exposure","volume":"354","author":"Emerson","year":"2022","journal-title":"Int J Cardiol"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.jcmg.2017.11.017","article-title":"Assessment of Left Ventricular Function by Echocardiography: The Case for Routinely Adding Global Longitudinal Strain to Ejection Fraction","volume":"11","author":"Potter","year":"2018","journal-title":"JACC Cardiovasc Imaging"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.jcmg.2019.07.018","article-title":"Comprehensive Assessment of Changes in Left Ventricular Diastolic Function With Contemporary Breast Cancer Therapy","volume":"13","author":"Upshaw","year":"2020","journal-title":"JACC: Cardiovasc Imaging"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12020693","article-title":"Does the Measurement of Ejection Fraction Still Make Sense in the HFpEF Framework? What Recent Trials Suggest","volume":"12","author":"Palazzuoli","year":"2023","journal-title":"J Clin Med"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15030986","article-title":"Global Longitudinal Strain in Cardio-Oncology: A Review","volume":"15","author":"S\u0142awi\u0144ski","year":"2023","journal-title":"Cancers"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0127044","article-title":"Left Ventricular Global Longitudinal Strain (GLS) Is a Superior Predictor of All-Cause and Cardiovascular Mortality When Compared to Ejection Fraction in Advanced Chronic Kidney Disease","volume":"10","author":"Krishnasamy","year":"2015","journal-title":"PLOS ONE"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s11912-022-01242-y","article-title":"Global Longitudinal Strain Monitoring to Guide Cardioprotective Medications During Anthracycline Treatment","volume":"24","author":"Marwick","year":"2022","journal-title":"Curr Oncol Rep"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.71766","article-title":"Role of Global Left Ventricle Longitudinal Strain and Cardiac Biomarkers in the Early Detection of Cancer Therapy-Related Dysfunction in Patients Treated With Cardiotoxic Chemotherapeutic Drugs in a Cardio-Oncology Clinic","volume":"16","author":"Shaaban","year":"2024","journal-title":"Cureus"},{"key":"ref84","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1200\/op.20.00924","article-title":"Monitoring for Chemotherapy-Related Cardiotoxicity in the Form of Left Ventricular Systolic Dysfunction: A Review of Current Recommendations","volume":"17","author":"Stone","year":"2021","journal-title":"JCO Oncol Pract"},{"key":"ref85","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1002\/ehf2.12159","article-title":"Left Ventricular Global Longitudinal Strain in Patients with Heart Failure with Preserved Ejection Fraction: Outcomes Following an Acute Heart Failure Hospitalization","volume":"4","author":"Buggey","year":"2017","journal-title":"ESC Heart Fail"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"384","DOI":"10.3390\/clinpract13020035","article-title":"Potential Role of Global Longitudinal Strain in Cardiac and Oncological Patients Undergoing Cardio-Oncology Rehabilitation (CORE)","volume":"13","author":"Cuomo","year":"2023","journal-title":"Clin Pract"},{"key":"ref87","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s10549-022-06586-4","article-title":"Risk of heart failure with preserved versus reduced ejection fraction in women with breast cancer","volume":"193","author":"Kwan","year":"2022","journal-title":"Breast Cancer Res Treat"},{"key":"ref88","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1136\/heartjnl-2021-319359","article-title":"The utility of strain imaging in the cardiac surveillance of bone marrow transplant patients","volume":"108","author":"Deshmukh","year":"2021","journal-title":"Heart"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13133904","article-title":"Left Atrial Strain as a Predictor of Early Anthracycline-Induced Chemotherapy-Related Cardiac Dysfunction: A Pilot Systematic Review and Meta-Analysis","volume":"13","author":"Goyal","year":"2024","journal-title":"J Clin Med"},{"key":"ref90","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1007\/s10554-023-02897-9","article-title":"Chemotherapy-related cardiac dysfunction: the usefulness of myocardial work indices","volume":"39","author":"Di","year":"2023","journal-title":"Int J Cardiovasc Imaging"},{"key":"ref91","doi-asserted-by":"publisher","first-page":"610","DOI":"10.21037\/cdt-20-165","article-title":"The use of cardiovascular magnetic resonance as an early non-invasive biomarker for cardiotoxicity in cardio-oncology","volume":"10","author":"Burrage","year":"2020","journal-title":"Cardiovasc Diagn Ther"},{"key":"ref92","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1007\/s00247-025-06260-z","article-title":"Cardiac magnetic resonance imaging in the assessment of cardiac injury and toxicity from cancer-related chemotherapy","volume":"55","author":"Johnson","year":"2025","journal-title":"Pediatr Radiol"}],"container-title":["Exploration of Targeted Anti-tumor Therapy"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T05:15:46Z","timestamp":1789362946000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.explorationpub.com\/Journals\/etat\/Article\/1002401"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,14]]},"references-count":92,"URL":"https:\/\/doi.org\/10.37349\/etat.2026.1002401","archive":["Portico","Portico"],"relation":{},"ISSN":["2692-3114"],"issn-type":[{"value":"2692-3114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,14]]},"assertion":[{"value":"2026-03-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-14","order":2,"name":"published","label":"Published Online","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"1002401"}}